Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 8/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | PAK4 | O96013 | 1/20 | 0.43 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 7/20 | 0.42 |
| ▸ | ULK1 | O75385 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15216600 | 0.90 | PAK1 (0.52) | IGF1RAURKAPAK4PAK1NTRK1 | |
| SCHEMBL15216601 | 0.87 | NTRK1 (0.46) | IGF1RAURKAPAK4PAK1NTRK1 | |
| SCHEMBL15216581 | 0.82 | PAK1 (0.57) | IGF1RAURKAPAK4PAK1 | |
| SCHEMBL15216592 | 0.81 | PAK1 (0.54) | AURKAPAK4PAK1 | |
| SCHEMBL15208636 | 0.75 | PAK1 (0.75) | IGF1RAURKAPAK4PAK1NTRK1 | |
| SCHEMBL15208718 | 0.75 | NTRK1 (0.45) | IGF1RPAK4PAK1NTRK1ULK1 | |
| SCHEMBL15217663 | 0.75 | PAK1 (0.70) | IGF1RAURKAPAK4PAK1 | |
| SCHEMBL15216468 | 0.73 | NTRK1 (0.62) | IGF1RPAK1NTRK1JAK2 | |
| SCHEMBL15216447 | 0.72 | PAK1 (0.59) | IGF1RAURKAPAK4PAK1 | |
| SCHEMBL15208160 | 0.72 | NTRK1 (0.47) | IGF1RNTRK1ULK1PDK1ULK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637537-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637537-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, RB1 | IGF1R 584/4885AURKA 395/4885PAK4 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.